Cytomedix purchased Aldagen for $16 million in stock, expanding the former's pipeline of regenerative therapies. The acquisition "provides Cytomedix with a novel, patent-protected cell selection technology that fits well with our existing commercial products and strengthens our long-range growth profile," Cytomedix CEO Martin Rosendale said.
Cytomedix acquires stem cell company Aldagen
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan